S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:APDN

Applied DNA Sciences - APDN Stock Forecast, Price & News

$1.47
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.41
$1.50
50-Day Range
$1.22
$1.69
52-Week Range
$0.62
$7.35
Volume
85,729 shs
Average Volume
164,629 shs
Market Capitalization
$18.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Applied DNA Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.1% Upside
$4.00 Price Target
Short Interest
Healthy
5.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of Applied DNA Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Industrial Products Sector

127th out of 183 stocks

Miscellaneous Business Services Industry

5th out of 6 stocks


APDN stock logo

About Applied DNA Sciences (NASDAQ:APDN) Stock

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

APDN Stock News Headlines

Applied DNA Sciences (NASDAQ:APDN) Lifted to Hold at StockNews.com
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Earnings Outlook For Applied DNA Sciences
APDN Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc. (APDN)
Applied DNA Launches Monkeypox Testing Service
See More Headlines
Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

APDN Company Calendar

Last Earnings
8/11/2021
Today
1/29/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Miscellaneous business services
Sub-Industry
N/A
Current Symbol
NASDAQ:APDN
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+172.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,270,000.00
Pretax Margin
-45.52%

Debt

Sales & Book Value

Annual Sales
$18.17 million
Book Value
$1.08 per share

Miscellaneous

Free Float
12,087,000
Market Cap
$18.98 million
Optionable
Optionable
Beta
0.53

Key Executives

  • James A. Hayward
    Chairman, President & Chief Executive Officer
  • Judy Murrah
    Chief Operating Officer
  • Beth M. Jantzen
    Chief Financial Officer & Controller
  • Lawrence Jung
    Associate Director-Research & Development
  • Frank Cipriani
    Associate Director-Production













APDN Stock - Frequently Asked Questions

Should I buy or sell Applied DNA Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied DNA Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APDN shares.
View APDN analyst ratings
or view top-rated stocks.

What is Applied DNA Sciences' stock price forecast for 2023?

1 brokerages have issued 1-year target prices for Applied DNA Sciences' shares. Their APDN share price forecasts range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 172.1% from the stock's current price.
View analysts price targets for APDN
or view top-rated stocks among Wall Street analysts.

How have APDN shares performed in 2023?

Applied DNA Sciences' stock was trading at $1.66 at the start of the year. Since then, APDN stock has decreased by 11.4% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

When is Applied DNA Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our APDN earnings forecast
.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) posted its earnings results on Wednesday, August, 11th. The technology company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.20. The technology company earned $1.70 million during the quarter, compared to analyst estimates of $3.44 million. Applied DNA Sciences had a negative net margin of 45.51% and a negative trailing twelve-month return on equity of 116.59%.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?

2 employees have rated Applied DNA Sciences Chief Executive Officer James A. Hayward on Glassdoor.com. James A. Hayward has an approval rating of 100% among the company's employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Applied DNA Sciences to a friend.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Ekso Bionics (EKSO), Micron Technology (MU), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Sorrento Therapeutics (SRNE) and Intel (INTC).

What is Applied DNA Sciences' stock symbol?

Applied DNA Sciences trades on the NASDAQ under the ticker symbol "APDN."

Who are Applied DNA Sciences' major shareholders?

Applied DNA Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied DNA Sciences' stock price today?

One share of APDN stock can currently be purchased for approximately $1.47.

How much money does Applied DNA Sciences make?

Applied DNA Sciences (NASDAQ:APDN) has a market capitalization of $18.98 million and generates $18.17 million in revenue each year. The technology company earns $-8,270,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How can I contact Applied DNA Sciences?

Applied DNA Sciences' mailing address is 50 HEALTH SCIENCES DRIVE, STONY BROOK NY, 11790. The official website for the company is www.adnas.com. The technology company can be reached via phone at (631) 240-8800, via email at investor@adnas.com, or via fax at 631-240-8900.

This page (NASDAQ:APDN) was last updated on 1/29/2023 by MarketBeat.com Staff